In an unexpected finding, phosphodiesterase inhibitors and sympathomimetics with α- and β-effect were strongly associated with higher AKI risk in this analysis. Large-scale studies examined potentially nephrotoxic drugs used to treat patients in the ICU.
Chronic kidney disease (CKD) is divided into five stages, ranging from stage 1 to stage 5. Each stage is determined by a blood test known as the estimated glomerular filtration rate (eGFR), which establishes how well your kidneys filter waste and excess fluid from your blood. With each stage of CKD, the function of your kidneys progressively worsens and requires different treatments to slow down kidney damage and to keep them working for as long as possible.
Even patients with advanced CKD or receiving dialysis appear to benefit from guideline-directed STEMI therapies, according to a retrospective study. Treatment and death risk among patients with ST-elevation myocardial infarction (STEMI) and chronic kidney disease (CKD) is understudied.